2,837
Views
7
CrossRef citations to date
0
Altmetric
RESEARCH ARTICLE

Transdermal iontophoresis delivery system for terazosin hydrochloride: an in vitro and in vivo study

, , , , , , , , , & show all
Pages 454-462 | Received 25 Dec 2020, Accepted 09 Feb 2021, Published online: 23 Feb 2021

References

  • Aa JY, Wang GJ, Hao HP, et al. (2010). Differential regulations of blood pressure and perturbed metabolism by total ginsenosides and conventional antihypertensive agents in spontaneously hypertensive rats. Acta Pharmacol Sin 31:930–7.
  • Abruzzo A, Cerchiara T, Luppi B, Bigucci F. (2019). Transdermal delivery of antipsychotics: rationale and current status. CNS Drugs 33:849–65.
  • Bhattaccharjee SA, Murnane KS, Banga AK. (2020). Transdermal delivery of breakthrough therapeutics for the management of treatment-resistant and post-partum depression. Int J Pharm 591:120007.
  • Byrne JD, Yeh JJ, Desimone JM. (2018). Use of iontophoresis for the treatment of cancer. J Control Release 284:144–51.
  • Cahusac PMB, Senok SS. (2020). Does hyaluronidase enhance drug penetration to mechanoreceptors? Skin Pharmacol Physiol 33:253–60.
  • Cázares-Delgadillo J, Ganem-Rondero A, Quintanar-Guerrero D, et al. (2010). Using transdermal iontophoresis to increase granisetron delivery across skin in vitro and in vivo: effect of experimental conditions and a comparison with other enhancement strategies. Eur J Pharm Sci 39:387–93.
  • Cheng X, Li H, Ge X, et al. (2020). Tumor-microenvironment- responsive size-shrinkable drug-delivery nanosystems for deepened penetration into tumors. Front Mol Biosci 7:576420.
  • Da Silva AA, Do Carmo JM, Kanyicska B, et al. (2008). Endogenous melanocortin system activity contributes to the elevated arterial pressure in spontaneously hypertensive rats. Hypertension 51:884–90.
  • Djabri A, Guy RH, Delgado-Charro MB. (2019). Potential of iontophoresis as a drug delivery method for midazolam in pediatrics. Eur J Pharm Sci 128:137–43.
  • Hundemer GL, Knoll GA, Petrcich W, et al. (2021). Kidney, cardiac, and safety outcomes associated with α-blockers in patients with CKD: a population-based cohort study. Am J Kidney Dis 77:178–89.
  • Işık D, Joshi AA, Guo X. (2021). Sulfoxide-functionalized nanogels inspired by the skin penetration properties of DMSO. Biomater Sci 9:712–25.
  • Kanikkannan N. (2002). Iontophoresis-based transdermal delivery systems. BioDrugs 16:339–47.
  • Kazemi M, Mombeiny R, Tavakol S, et al. (2019). A combination therapy of nanoethosomal piroxicam formulation along with iontophoresis as an anti-inflammatory transdermal delivery system for wound healing. Int Wound J 16:1144–52.
  • Lapteva M, Sallam MA, Goyon A, et al. (2020). Non-invasive targeted iontophoretic delivery of cetuximab to skin. Expert Opin Drug Deliv 17:589–602.
  • Marro D, Kalia YN, Delgado-Charro MB, Guy RH. (2001). Contributions of electromigration and electroosmosis to iontophoretic drug delivery. Pharm Res 18:1701–8.
  • Melville S, Teskey R, Philip S, et al. (2018). A comparison and calibration of a wrist-worn blood pressure monitor for patient management: assessing the reliability of innovative blood pressure devices. J Med Internet Res 20:e111.
  • Mohammed MI, Makky AM, Teaima MH, et al. (2016). Transdermal delivery of vancomycin hydrochloride using combination of nano-ethosomes and iontophoresis: in vitro and in vivo study. Drug Deliv 23:1558–64.
  • Murota H, Kotobuki Y, Yamaga K, Yoshioka Y. (2020). Female child with hematidrosis of the palm: case report and published work review. J Dermatol 47:166–8.
  • Nugroho AK, Li L, Dijkstra D, et al. (2005). Transdermal iontophoresis of the dopamine agonist 5-OH-DPAT in human skin in vitro. J Control Release 103:393–403.
  • Oestreich MC, Vernooij RW, Sathianathen NJ, et al. (2020). Alpha-blockers after shock wave lithotripsy for renal or ureteral stones in adults. Cochrane Database Syst Rev 11:CD013393.
  • Panchagnula R, Pillai O, Nair VB, Ramarao P. (2000). Transdermal iontophoresis revisited. Curr Opin Chem Biol 4:468–73.
  • Piascik MT, Perez DM. (2001). Alpha1-adrenergic receptors: new insights and directions. J Pharmacol Exp Ther 298:403–10.
  • Shelke NB, Sairam M, Halligudi SB, Aminabhavi TM. (2007). Development of transdermal drug‐delivery films with castor‐oil‐based polyurethanes. J Appl Polym Sci 103:779–88.
  • Telò I, Tratta E, Guasconi B, et al. (2016). In-vitro characterization of buccal iontophoresis: the case of sumatriptan succinate. Int J Pharm 506:420–8.
  • Titmarsh S, Monk JP. (1987). Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension. Drugs 33:461–77.
  • Wan J, Qiu Z, Ding Y, et al. (2018). The expressing patterns of opioid peptides, anti-opioid peptides and their receptors in the central nervous system are involved in electroacupuncture tolerance in goats. Pharmaceutics 12:902.
  • Wanasathop A, Li SK. (2018). Iontophoretic drug delivery in the oral cavity. Pharmaceutics 10:121.
  • Wiedersberg S, Guy RH. (2014). Transdermal drug delivery: 30+ years of war and still fighting!. J Control Release 190:150–6.
  • Yamada M, Prow TW. (2020). Physical drug delivery enhancement for aged skin, UV damaged skin and skin cancer: translation and commercialization. Adv Drug Deliv Rev 153:2–17.
  • Yamaga K, Yoshioka Y, Fukuta T, et al. (2020). Non-invasive delivery of biological macromolecular drugs into the skin by iontophoresis and its application to psoriasis treatment. J Dermatol 323:323–32.
  • Yang CH, Raja A. (2020). Terazosin. Treasure Island (FL): StatPearls Publishing.
  • Zhang Y, Yu J, Kahkoska AR, et al. (2019). Advances in transdermal insulin delivery. Adv Drug Deliv Rev 139:51–70.